Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Development of a Text Message-based Headache Diary in Adolescents and Children
Headache
P14 - Poster Session 14 (8:00 AM-9:00 AM)
7-010

To examine the feasibility of a text message-based diary for collecting daily headache symptoms in adolescents and children with headache.
The International Guidelines for preventative treatment of migraine recommends prospective collection of a headache diary that captures migraine symptoms. Historically this was done on paper, but studies in other populations have suggested increased compliance via electronic diary. It is estimated that 95% of teenagers in the United States have access to a cell phone with 90% saturation across socioeconomic groups. Text messages may be a promising platform for headache diary collection.
Participants were recruited from 2 larger projects–a study validating a scale of patient expectancy and a trial of occipital nerve blocks for status migrainosus. We developed a text message-based, interactive, HIPAA-compliant headache diary based on the NINDS Common Data Elements that collects headache characteristics, medication use, and daily disability. The diary sends daily messages for 4 or 12 weeks depending on treatment. Questions are based on participant response, sending 3-5 core questions daily. 
As of date in this pilot, 28 participants (19 female) completed the diary since November 2018. Twenty participants (12 female) were recruited into the 4-week arm; eight participants (7 female) into the 12-week arm. We have collected 941 partially and 867 fully completed entries. Two 4-week participants withdrew during follow-up. All remaining participants provided partially or fully completed entries on at least 75% of days, with a by-participant mean of 80% and 87% of entries fully completed despite withdrawals. One 4-week participant reported that the questions were “confusing” 1 of 4 weeks, but otherwise feedback was neutral or positive.
Text messages appear to be a promising method for collecting patient-reported data. We plan to continue enrollment with a goal of at least 120 participants across both projects.
Authors/Disclosures
Danielle J. Kellier
PRESENTER 		The institution of Ms. Kellier has received research support from National Institute of Neurological Disorders and Stroke.
Dana Haagen No disclosure on file
Blanca Marquez de Prado An immediate family member of Blanca Marquez de Prado has stock in Latus Bio. An immediate family member of Blanca Marquez de Prado has received intellectual property interests from a discovery or technology relating to health care.
No disclosure on file
No disclosure on file
No disclosure on file
Nichelle Raj Nichelle Raj has nothing to disclose.
John T. Farrar, MD (Univ of PA Medical Center) Dr. Farrar has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Vertex Pharma. Dr. Farrar has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for PharamcoEpidemiology and Drug Safety. The institution of Dr. Farrar has received research support from Food and Drug Administration . The institution of Dr. Farrar has received research support from NIH .
Andrew D. Hershey, MD, PhD, FAHS, FÂ鶹´«Ã½Ó³»­ The institution of Dr. Hershey has received personal compensation in the range of $0-$499 for serving as a Consultant for Amgen. The institution of Dr. Hershey has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lundbeck. The institution of Dr. Hershey has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Supernus. The institution of Dr. Hershey has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Upsher-Smith. The institution of Dr. Hershey has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Teva. The institution of Dr. Hershey has received research support from Amgen. The institution of Dr. Hershey has received research support from NIH, NINDS. The institution of Dr. Hershey has received research support from Bioahaven. The institution of Dr. Hershey has received research support from Upsher-Smith. Dr. Hershey has received publishing royalties from a publication relating to health care.
Christina L. Szperka, MD, FÂ鶹´«Ã½Ó³»­ (Children's Hospital of Philadelphia) The institution of Dr. Szperka has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Teva. The institution of Dr. Szperka has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abbvie. The institution of Dr. Szperka has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lundbeck. Dr. Szperka has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eli Lilly. Dr. Szperka has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Upsher Smith. The institution of Dr. Szperka has received research support from PCORI. Dr. Szperka has a non-compensated relationship as a Cochair Scientific Committee with American Headache Society that is relevant to Â鶹´«Ã½Ó³»­ interests or activities.